Autolus Therapeutics (NASDAQ:AUTL) Price Target Cut to $10.00 by Analysts at Truist Financial

Autolus Therapeutics (NASDAQ:AUTL - Free Report) had its price objective reduced by Truist Financial from $11.00 to $10.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

AUTL has been the topic of several other research reports. Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Wells Fargo & Company decreased their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock traded up $0.16 on Tuesday, hitting $1.57. The company had a trading volume of 2,062,279 shares, compared to its average volume of 1,401,553. The stock has a market capitalization of $417.77 million, a price-to-earnings ratio of -1.30 and a beta of 2.07. Autolus Therapeutics has a 1 year low of $1.39 and a 1 year high of $5.84. The stock has a 50 day moving average of $1.92 and a 200-day moving average of $2.77.

Remove Ads

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million. Equities analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors have recently added to or reduced their stakes in AUTL. Wellington Management Group LLP raised its holdings in Autolus Therapeutics by 4.6% during the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after acquiring an additional 1,125,454 shares during the period. TFG Asset Management GP Ltd raised its stake in shares of Autolus Therapeutics by 3.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company's stock valued at $19,388,000 after purchasing an additional 250,000 shares during the period. Two Sigma Advisers LP boosted its stake in Autolus Therapeutics by 4.8% in the 4th quarter. Two Sigma Advisers LP now owns 333,400 shares of the company's stock worth $783,000 after purchasing an additional 15,400 shares during the period. Two Sigma Investments LP grew its holdings in Autolus Therapeutics by 23.8% during the 4th quarter. Two Sigma Investments LP now owns 906,767 shares of the company's stock valued at $2,131,000 after buying an additional 174,485 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Autolus Therapeutics during the fourth quarter valued at about $581,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.